These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22807156)

  • 21. NR2B subunit of NMDA receptor at nucleus accumbens is involved in morphine rewarding effect by siRNA study.
    Kao JH; Huang EY; Tao PL
    Drug Alcohol Depend; 2011 Nov; 118(2-3):366-74. PubMed ID: 21601998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long lasting changes in morphine-induced mesolimbic dopamine release after chronic morphine exposure.
    Spanagel R; Almeida OF; Shippenberg TS
    Synapse; 1993 Jul; 14(3):243-5. PubMed ID: 8211708
    [No Abstract]   [Full Text] [Related]  

  • 23. Possible involvement of protease-activated receptor-1 in the regulation of morphine-induced dopamine release and hyperlocomotion by the tissue plasminogen activator-plasmin system.
    Ito M; Nagai T; Mizoguchi H; Fukakusa A; Nakanishi Y; Kamei H; Nabeshima T; Takuma K; Yamada K
    J Neurochem; 2007 Jun; 101(5):1392-9. PubMed ID: 17286591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GABAA receptors in VTA mediate the morphine-induced release of ascorbic acid in rat nucleus accumbens.
    Sun JY; Yang JY; Wang F; Hou Y; Dong YX; Wu CF
    Brain Res; 2011 Jan; 1368():52-8. PubMed ID: 20965157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The non-peptidic delta opioid receptor agonist TAN-67 enhances dopamine efflux in the nucleus accumbens of freely moving rats via a mechanism that involves both glutamate and free radicals.
    Fusa K; Takahashi I; Watanabe S; Aono Y; Ikeda H; Saigusa T; Nagase H; Suzuki T; Koshikawa N; Cools AR
    Neuroscience; 2005; 130(3):745-55. PubMed ID: 15590157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra-VTA adenosine A1 receptor activation blocks morphine stimulation of motor behavior and cortical and limbic Fos immunoreactivity.
    Kaplan GB; Leite-Morris KA; Klufas MA; Fan W
    Eur J Pharmacol; 2009 Jan; 602(2-3):268-76. PubMed ID: 19027733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of dopamine-induced hypermotility following injection of various opioids into the nucleus accumbens.
    Erdö F; Polgár K; Máté I; Székely JI
    Acta Physiol Hung; 1990; 76(3):219-27. PubMed ID: 1966032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low doses of dextromethorphan attenuate morphine-induced rewarding via the sigma-1 receptor at ventral tegmental area in rats.
    Chen SL; Hsu KY; Huang EY; Lu RB; Tao PL
    Drug Alcohol Depend; 2011 Sep; 117(2-3):164-9. PubMed ID: 21320758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect.
    Valverde O; Noble F; Beslot F; Daugé V; Fournié-Zaluski MC; Roques BP
    Eur J Neurosci; 2001 May; 13(9):1816-24. PubMed ID: 11359533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of mu-, delta- and kappa-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice.
    Mori T; Ito S; Kita T; Narita M; Suzuki T; Sawaguchi T
    Eur J Pharmacol; 2006 Feb; 532(1-2):81-7. PubMed ID: 16464448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment of opioid-induced rewarding effects under oxaliplatin- and Paclitaxel-induced neuropathy in rats.
    Mori T; Kanbara T; Harumiya M; Iwase Y; Masumoto A; Komiya S; Nakamura A; Shibasaki M; Kanemasa T; Sakaguchi G; Suzuki T
    J Pharmacol Sci; 2014; 126(1):47-55. PubMed ID: 25141998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference.
    Andrews N; Loomis S; Blake R; Ferrigan L; Singh L; McKnight AT
    Psychopharmacology (Berl); 2001 Oct; 157(4):381-7. PubMed ID: 11605097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphine reward in dopamine-deficient mice.
    Hnasko TS; Sotak BN; Palmiter RD
    Nature; 2005 Dec; 438(7069):854-7. PubMed ID: 16341013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.
    Narita M; Takei D; Shiokawa M; Tsurukawa Y; Matsushima Y; Nakamura A; Takagi S; Asato M; Ikegami D; Narita M; Amano T; Niikura K; Hashimoto K; Kuzumaki N; Suzuki T
    Eur J Pharmacol; 2008 Dec; 600(1-3):105-9. PubMed ID: 18955042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission.
    Piazza PV; Barrot M; Rougé-Pont F; Marinelli M; Maccari S; Abrous DN; Simon H; Le Moal M
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15445-50. PubMed ID: 8986831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uridine decreases morphine-induced behavioral sensitization by decreasing dorsal striatal dopamine release possibly via agonistic effects at GABAA receptors.
    Liu P; Wu C; Song W; Yu L; Yang X; Xiang R; Wang F; Yang J
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1557-66. PubMed ID: 25088943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unidirectional opioid-cannabinoid cross-tolerance in the modulation of social play behavior in rats.
    Schiavi S; Manduca A; Segatto M; Campolongo P; Pallottini V; Vanderschuren LJMJ; Trezza V
    Psychopharmacology (Berl); 2019 Sep; 236(9):2557-2568. PubMed ID: 30903212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different effects on dopamine release in nucleus accumbens in mice by the morphine metabolites morphine-6-glucuronide and morphine-3-glucuronide.
    Vindenes V; Pettersen BS; Gottås A; Christiansen NL; Boix F; Mørland J
    Basic Clin Pharmacol Toxicol; 2009 Nov; 105(5):357-60. PubMed ID: 19663818
    [No Abstract]   [Full Text] [Related]  

  • 39. Modulation of rat brain cannabinoid receptors after chronic morphine treatment.
    Rubino T; Tizzoni L; Viganò D; Massi P; Parolaro D
    Neuroreport; 1997 Oct; 8(15):3219-23. PubMed ID: 9351646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracerebroventricular injections of dronabinol, a cannabinoid receptor agonist, does not attenuate serotonin-induced apnea in Sprague-Dawley rats.
    Calik MW; Carley DW
    J Negat Results Biomed; 2016 May; 15():8. PubMed ID: 27133202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.